of the VEGFR-2 signaling pathway has already become an attractive approach for cancer therapy. In this study, a novel pyrimidine-based derivative 7j was designed as lead compound, and three series of potent VEGFR-2 inhibitors were synthesized and biologically evaluated against A549 and HepG2 cell lines. Compounds 7d, 9s and 13n exhibited superior inhibitory activities against A549 cell with IC50 ranged
血管内皮生长因子受体2(V
EGFR-2)在肿瘤血管生成中起着至关重要的作用,而抑制V
EGFR-2信号通路已经成为癌症治疗的一种有吸引力的方法。在这项研究中,设计了一种新型的基于
嘧啶的衍
生物7j作为前导化合物,合成了三组有效的V
EGFR-2
抑制剂,并针对A549和HepG2
细胞系进行了
生物学评估。与Pazopanib(IC 50)相比,化合物7d,9s和13n对A549细胞的IC 50为9.19至13.17μM,对HepG2细胞的IC 50为11.94至18.21μM。 = 21.18和36.66μM)。另外,进行了分子对接研究以研究目标化合物与V
EGFR-2之间的结合能力和结合方式。